Novo Nordisk A/S (NVO) Eyes Solidifying Its Market Position with Increased Advertising Spending

According to a January 28, 2026, Reuters report, Novo Nordisk A/S (NYSE:NVO) accrued its advertizing spending for its GLP-1 medicine successful the U.S. In the archetypal 9 months of 2025, the institution allocated astir $500 cardinal to beforehand Wegovy and Ozempic. The allocated fund is much than doubly Eli Lilly’s spending connected rival treatments.

As proviso constraints eased and competitory pressures increased, Novo spent $316 cardinal connected Wegovy and $169 cardinal connected Ozempic, according to MediaRadar. This highlights year-over-year increases of 54% and 44%, respectively.

The accrued advertizing reflects Novo’s efforts to support its marketplace presumption aft Eli Lilly’s Zepbound showcased greater weight-loss efficacy successful precocious 2024 proceedings data, surpassing Wegovy successful U.S. medicine volume. Novo’s absorption besides plans to instantly beforehand its upcoming oral mentation of Wegovy and boost organisation done cash-pay and direct-to-consumer channels.

On the anterior day, Citi initiated sum of Novo Nordisk A/S (NYSE:NVO) with a ‘Neutral’ standing and a DKK 400 terms target, noting that the company’s valuation appears just astatine existent levels contempt continued precocious request for obesity treatments.

Novo Nordisk A/S (NYSE:NVO), a planetary pharmaceutical company, specializes successful treating uncommon diseases, diabetes, and obesity.

While we admit the imaginable of NVO arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the champion short-term AI stock.

READ NEXT: What Are the Best Stocks to Buy Right Now? and 10 Stocks Under $1 That Will Explode.

Disclosure: None.